SCHEMBL3602094

SCHEMBL3602094

CCOC(=O)C(O)(c1cn(Cc2ccccc2)c2cc(N)ccc12)C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.42
PTPN1 P18031 1/20 0.41
F2RL3 Q96RI0 1/20 0.40
SERPINE1 P05121 1/20 0.39
MAPK1 P28482 2/20 0.39
P2RX3 P56373 1/20 0.39
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
PLA2G2A P14555 2/20 0.37
THRB P10828 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
POLB P06746 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3591579 0.92 PTPN1 (0.46) GLAPTPN1F2RL3SERPINE1MAPK1
SCHEMBL3600671 0.89 PTPN1 (0.47) GLAPTPN1F2RL3SERPINE1MAPK1
SCHEMBL3600338 0.89 GLA (0.43) GLAPTPN1F2RL3SERPINE1MAPK1
SCHEMBL3598494 0.88 F2RL3 (0.45) GLAPTPN1F2RL3SERPINE1MAPK1
SCHEMBL3592319 0.88 GLA (0.52) GLAPTPN1F2RL3MAPK1POLB
SCHEMBL3588733 0.87 MAPK1 (0.42) GLAPTPN1F2RL3SERPINE1MAPK1
SCHEMBL3596187 0.86 GLA (0.40) GLAPTPN1F2RL3SERPINE1MAPK1
SCHEMBL13254027 0.86 PTPN1 (0.41) GLAPTPN1F2RL3SERPINE1MAPK1
SCHEMBL3600955 0.86 PPARG (0.49) GLAPTPN1SERPINE1L3MBTL1
SCHEMBL3590933 0.85 AR (0.40) GLAPTPN1F2RL3SERPINE1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE NR3C1, NR3C2, NR0B1 GLA 3982/4885PTPN1 752/4885F2RL3 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.